[go: up one dir, main page]

WO1997041850A1 - Paclitaxel pour le traitement d'affections rhumatismales - Google Patents

Paclitaxel pour le traitement d'affections rhumatismales Download PDF

Info

Publication number
WO1997041850A1
WO1997041850A1 PCT/KR1996/000183 KR9600183W WO9741850A1 WO 1997041850 A1 WO1997041850 A1 WO 1997041850A1 KR 9600183 W KR9600183 W KR 9600183W WO 9741850 A1 WO9741850 A1 WO 9741850A1
Authority
WO
WIPO (PCT)
Prior art keywords
paclitaxel
treatment
mice
disease
rheumatic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR1996/000183
Other languages
English (en)
Inventor
Yeong Wook Song
Kyung Man Hong
Eun Sook Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU73413/96A priority Critical patent/AU7341396A/en
Publication of WO1997041850A1 publication Critical patent/WO1997041850A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On a découvert que la paclitaxel a un effet puissant sur la protection contre le développement d'affections rhumatismales. Il est un agent puissant pour le traitement d'affections rhumatismales, en particulier le lupus érythémateux aigu disséminé.
PCT/KR1996/000183 1996-05-02 1996-10-26 Paclitaxel pour le traitement d'affections rhumatismales Ceased WO1997041850A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73413/96A AU7341396A (en) 1996-05-02 1996-10-26 Paclitaxel for the treatment of rheumatic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019960014189A KR100191446B1 (ko) 1996-05-02 1996-05-02 파클리탁셀 함유 전신성 홍반성 낭창치료제
KR1996/14189 1996-05-02

Publications (1)

Publication Number Publication Date
WO1997041850A1 true WO1997041850A1 (fr) 1997-11-13

Family

ID=19457526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1996/000183 Ceased WO1997041850A1 (fr) 1996-05-02 1996-10-26 Paclitaxel pour le traitement d'affections rhumatismales

Country Status (3)

Country Link
KR (1) KR100191446B1 (fr)
AU (1) AU7341396A (fr)
WO (1) WO1997041850A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000928A1 (fr) * 1991-07-08 1993-01-21 Rhone-Poulenc Rorer S.A. Nouvelles compositions a base de derives de la classe des taxanes
WO1994012172A1 (fr) * 1992-12-02 1994-06-09 Thomas Jefferson University Methodes d'eliminiation de parasites protozoaires
WO1994012198A1 (fr) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Composition a base de taxol injectable
WO1994012171A1 (fr) * 1992-12-02 1994-06-09 Rhone-Poulenc Rorer S.A. Compositions injectables a base de derives des taxanes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000928A1 (fr) * 1991-07-08 1993-01-21 Rhone-Poulenc Rorer S.A. Nouvelles compositions a base de derives de la classe des taxanes
WO1994012198A1 (fr) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Composition a base de taxol injectable
WO1994012172A1 (fr) * 1992-12-02 1994-06-09 Thomas Jefferson University Methodes d'eliminiation de parasites protozoaires
WO1994012171A1 (fr) * 1992-12-02 1994-06-09 Rhone-Poulenc Rorer S.A. Compositions injectables a base de derives des taxanes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS & RHEUMATISM, June 1994, Volume 37, No. 36, BRAHN E. et al., "Regression of Collagen-Induced Arthritis with Taxol, a Microtubule Stabilizer", pp. 839-845. *
CELLULAR IMMUNOLOGY, August 1994, Volume 157, No. 1, OLIVER S.J. et al., "Suppression of Collagen-Induced Arthritis Using an Angiogenesis Inhibitor, AGM-1470 and a Microtubule Stabilizer, Taxol", pp. 291-299. *
CHEMICAL ABSTRACTS, Vol. 106, No. 22, 01 June 1987, (Columbus, Ohio, USA), page 405, Abstract No. 182581c, B.D. TARR et al., "A New Parenteral Vehicle for the Administration of Some Poorly Water Soluble Anti-Cancer Drugs"; & J. PARENTER. SCI. TECHNOl., 41(1), 31-3, (ENG). *

Also Published As

Publication number Publication date
KR100191446B1 (ko) 1999-06-15
KR970073582A (ko) 1997-12-10
AU7341396A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
Vorup-Jensen et al. Structural immunology of complement receptors 3 and 4
Akhtari et al. Neutropenia in a patient treated with ipilimumab (anti–CTLA-4 antibody)
Drach et al. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid
US20130022609A1 (en) Method of treating androgen independent prostate cancer
CZ111595A3 (cs) Dithiokarbamáty pro ošetřování aterosklerózy a jiných kardiovaskulátních a zánětlivých chorob
RU2472526C2 (ru) Фармацевтическая композиция, содержащая анти-cd6 моноклональное антитело, пригодная для диагностики и лечения ревматоидного артрита
RU2177316C2 (ru) Фармацевтическая композиция для лечения рака и вирусных заболеваний, способ лечения рака, способ лечения вирусных инфекций на ее основе
JP2005538093A (ja) 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
KR19990036138A (ko) 암 성장을 억제하기 위한 플루코나졸의 용도
van Vuuren et al. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model
Ohnuma et al. Phase 1 study of intravenous rigosertib (ON 01910. Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer
SK14098A3 (en) Use of 1h-1,2,4-triazole derivatives for inhibiting the growth of cancers
Collins et al. The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells
Song et al. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice
AU2008265974A1 (en) Use of TACI-Ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
AU2019235626A1 (en) Combination of CD47 blockade therapy and a CD38 antibody
Asako et al. Phalloidin prevents leukocyte emigration induced by proinflammatory stimuli in rat mesentery
KR20160087037A (ko) 혈관석회화 방지용 조성물 및 이를 포함하는 혈관 석회화 치료제
WO1997041850A1 (fr) Paclitaxel pour le traitement d'affections rhumatismales
US6972175B2 (en) Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
EP2143436B1 (fr) Produit cd6 destiné au traitement de maladies infectieuses et de processus inflammatoires liés
WO2021108637A1 (fr) Compositions et méthodes pour traiter des maladies et des états de santé par déplétion d'adn mitochondrial ou génomique de la circulation
US20120288495A1 (en) Therapeutic compositions and methods
Zhou et al. The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies
Cameron et al. Dantrolene, an inhibitor of intracellular calcium release, fails to increase survival in a rat model of intra-abdominal sepsis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN HU JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97539755

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA